Ralf Kronenwett

List of Publications by Year
in descending order

9 papers	1,325 citations	1040056 9 h-index	1474206 9 g-index
9 all docs	9 docs citations	9 times ranked	1553 citing authors

#	Article	IF	Citations
1	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clinical Cancer Research, 2011, 17, 6012-6020.	7.0	597
2	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptorâ€"Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	7.1	246
3	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute, 2016, 108, djw149.	6.3	165
4	Decentral gene expression analysis for ER+/Her2âˆ' breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 251-259.	2.8	88
5	Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer, 2012, 12, 456.	2.6	66
6	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment, 2019, 176, 377-386.	2.5	61
7	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2âˆ' Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clinical Cancer Research, 2019, 25, 3865-3872.	7.0	54
8	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. European Journal of Cancer, 2020, 134, 99-106.	2.8	29
9	Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Annals of Surgical Oncology, 2020, 27, 765-771.	1.5	19